Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $25

7/11/24 6:59:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $30 to $25.

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SDGR

Date	Price Target	Rating	Analyst
7/2/2024	$29.00	Outperform	Leerink Partners
12/5/2023	$38.00	Overweight	KeyBanc Capital Markets
5/5/2023	$60.00	Overweight	Piper Sandler
12/19/2022	$23.00	Neutral	Goldman
3/1/2022	$55.00	Buy	Citigroup
11/19/2021	$82.00 → $49.00	Overweight → Equal-Weight	Morgan Stanley
11/19/2021	$87.00	Overweight	Piper Sandler
11/11/2021	$80.00 → $52.00	Buy → Neutral	B of A Securities